Duane Day: A Novel Assay for Measuring Active Factor XIa
Duane Day, Co-Owner at Innovative Research, shared Innovative Research’s post on LinkedIn:
“I’ve spent a good part of my career in the contact activation system, going back to my research days at Henry Ford Hospital in the 1980’s (I am getting old). So I’ll admit it: I’m genuinely excited about this one.
Factor XIa has become one of the most closely watched targets in anticoagulation. But most Factor XI assays tell you how much protein is there, not how much of it is actually active. That gap matters, whether you’re developing an inhibitor, studying contact activation, or checking a plasma-derived product for unwanted FXIa.
Our team at Innovative Research built the Human Factor XIa ELISA Kit to close it. It uses a functional serpin trap that captures only the catalytically active enzyme, washes away the inactive zymogen or XIa inhibitor complexes, and then confirms identity with an anti-Factor XI antibody. You’re measuring free, active FXIa, not total antigen.
A few details for the bench scientists:
- Range of 0.2 to 100 ng/mL
- Calibrated to the WHO/NIBSC 13/100 reference
- Works with plasma, cell culture supernatants, lysates and other biological fluids
- Detects both native and recombinant human FXIa
Proud of the people at IR who made this happen. If FXIa is part of your work, we would love to hear how you might use it.”
Innovative Research shared a post on LinkedIn:
“Your Factor XI assay can tell you how much protein is there.
It can’t tell you how much of it is active.
That’s the gap our new Human Factor XIa ELISA Kit was built to close.
Using functional serpin-trap capture, it quantifies free, catalytically active Factor XI (FXIa), not the inactive zymogen. The result is a true functional readout of coagulation activation.
What’s inside:
- Covalent capture with biotinylated human PAI-1
- Assay range of 0.2–100 ng/mL
- Calibrated against WHO/NIBSC reference 13/100
- Results in under 2.5 hours
- Recognizes native and recombinant human FXIa
See the assay principle and full specs here.”
Stay updated with Hemostasis Today.
-
Nov 5, 2026, 13:20Bruno Pougault։ D-Dimer in Infection and Suspected VTE
-
Nov 5, 2026, 13:07Five-Year Outcomes of Hemophilia Gene Therapy – Global Hemophilia Report
-
Nov 5, 2026, 12:59Marius Tanase։ Building Stronger Partnerships for Better Bleeding Disorders Care
-
Nov 5, 2026, 12:43George Giannakoulas: NLR as a Predictor of Outcomes in Acute Coronary Syndromes
-
Nov 5, 2026, 12:31Jessica Kruger: The Educational Potential of Hemophilia Treatment Centers
-
Nov 5, 2026, 12:16Noor Aswad։ 200 Kilometers for a More Inclusive Future
-
Nov 5, 2026, 12:07EHC in Romania – Working Towards Better Patient Care
-
Nov 5, 2026, 11:56Mohamed Magdy: Blood Transfusion Reactions – High-Yield Summary
-
Nov 5, 2026, 09:48Kanza Khan: Hematology and Diagnostic Laboratory Techniques